A pharmaceutical company’s cancer drug combination has demonstrated effectiveness in treating an aggressive form of blood cancer, though it comes with increased risks of adverse reactions.
The drug combination featuring the company’s Monjuvi medication, along with a Bristol Myers Squibb treatment called Revlimid and a standard chemotherapy protocol known as R-CHOP, lowered the chances of disease advancement, return, or patient death by 25% when compared to the standard treatment by itself.
The pharmaceutical firm initially shared these findings in January and indicated that comprehensive survival statistics for the drug mixture would be available at a future time. The company’s research chief, Pablo Cagnoni, described the survival analysis as being in its “early” stages while noting it demonstrated a distinct pattern of enhancement.
The clinical study examined the effectiveness of combining Monjuvi, Bristol Myers Squibb’s Revlimid, and R-CHOP against R-CHOP treatment alone. The trial involved approximately 900 patients who had recently been diagnosed with diffuse large B-cell lymphoma, which represents the most prevalent form of non-Hodgkin lymphoma.
Medical experts and financial stakeholders had been eagerly awaiting additional information about side effects and treatment discontinuation rates from this intensive multi-medication approach.
Serious negative reactions occurred more frequently among patients receiving the Monjuvi combination, affecting nearly 87% compared to 76% of those who received only R-CHOP, a treatment involving five different medications.
Treatment cessation due to therapy-related complications was also elevated at 25.7%, in contrast to 18% for the standard approach. Fatalities attributed to adverse reactions reached 6% in the group receiving the company’s drug combination, while the standard care group experienced 3.8%.
Despite these concerns, the overall mortality rate was actually lower for the combination therapy at 18.5%, compared to 21.7% for R-CHOP alone.
“Sometimes when you add another drug, you obviously see a little bit more side effects, which is why it’s so important to report the survival data, because all of this gets integrated into survival,” explained the company’s Cagnoni.
These comprehensive findings were shared at the American Society of Clinical Oncology conference held in Chicago.
Cagnoni noted that more than half of high-risk patients currently receiving R-CHOP treatment could qualify for this new treatment approach as their initial therapy once regulatory approval is obtained.
Government statistics indicate that between 18,000 and 25,000 Americans receive this cancer diagnosis annually.
The medication Monjuvi, scientifically known as tafasitamab, has already received expedited approval in the United States when used alongside Revlimid for patients whose condition has returned or failed to respond to previous treatments, particularly those ineligible for stem cell transplantation.
The company plans to pursue broader approval in both the United States and Europe for using this combination therapy as an initial treatment for newly diagnosed patients.
“This doubles the potential eligible population,” Cagnoni stated.
